Source: Virtual Congress 2021 – Therapy of pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
J. Porszasz (Torrance, United States of America), L. Holdstock (Research Triangle Park, United States of America), S. Blonshine (Mason, United States of America), R. Casaburi (Torrance, United States of America), D. Yehle (Research Triangle Park, United States of America), M. Cunningham (Research Triangle Park, United States of America), J. Blonshine (Mason, United States of America), R. Oudiz (Torrance, United States of America), M. Guazzi (Milan, Italy), F. Torres (Dallas, United States of America), R. Benza (Columbus, United States of America), J. Vachiery (Erasme Academic Hospital, Belgium). Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY. 1931

Member's Comments

No comment yet.

Related content which might interest you: End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety. Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001 Multicentre trials on specialised exercise training and rehabilitation are useful in patients with pulmonary hypertension Source: Eur Respir J, 54 (5) 1901631; 10.1183/13993003.01631-2019 Year: 2019 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Biological quality control for spirometry in a multi-centred clinical trial Source: Annual Congress 2008 - Quality spirometry: the only spirometry! Year: 2008 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: Randomised controlled trial Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 Exercise training improves peak oxygen consumption and hemodynamics in patients with pulmonary hypertension – A prospective, randomized, controlled trial Source: International Congress 2016 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2016 Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Source: Eur Respir J 2007; 29: 432-434 Year: 2007 New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Maintenance after pulmonary rehabilitation in COPD: a randomised trial. Preliminary results Source: Eur Respir J 2004; 24: Suppl. 48, 245s Year: 2004 Safety and efficacy of home-based pulmonary rehabilitation in patients with pulmonary hypertension: Feasibility study of 12 cases Source: Virtual Congress 2020 – Comprehensive care and pulmonary rehabilitation for chronic respiratory diseases Year: 2020 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension Source: Eur Respir J 2015; 45: 1314-1322 Year: 2015